Corgard Related Published Studies
Well-designed clinical trials related to Corgard (Nadolol / Bendroflumethiazide)
Controlled trial of ligation plus nadolol versus nadolol alone for the prevention of first variceal bleeding. [2010.07]
Nadolol plus isosorbide mononitrate alone or associated with band ligation in the prevention of recurrent bleeding: a multicentre randomised controlled trial. [2009.08]
Clinical trial: a randomized controlled study on prevention of variceal rebleeding comparing nadolol + ligation vs. hepatic venous pressure gradient-guided pharmacological therapy. [2009.02.15]
Comparison of endoscopic variceal ligation and nadolol plus isosorbide-5-mononitrate in the prevention of first variceal bleeding in cirrhotic patients. [2006.10]
Comparative study between nadolol and 5-isosorbide mononitrate vs. endoscopic band ligation plus sclerotherapy in the prevention of variceal rebleeding in cirrhotic patients: a randomized controlled trial. [2006.08.15]
Evaluation of endoscopic variceal ligation (EVL) versus propanolol plus isosorbide mononitrate/nadolol (ISMN) in the prevention of variceal rebleeding: comparison of cirrhotic and noncirrhotic patients. [2005.08]
Variceal ligation plus nadolol compared with ligation for prophylaxis of variceal rebleeding: a multicenter trial. [2005.03]
A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis. [2004.08]
Endoscopic ligation vs. nadolol in the prevention of first variceal bleeding in patients with cirrhosis. [2004.03]
Nadolol plus spironolactone in the prophylaxis of first variceal bleed in nonascitic cirrhotic patients: A preliminary study. [2003.02]
Banding ligation versus nadolol and isosorbide mononitrate for the prevention of esophageal variceal rebleeding. [2002.09]
Nadolol is superior to isosorbide mononitrate for the prevention of the first variceal bleeding in cirrhotic patients with ascites. [2002.09]
Vasovagal syncope: a prospective, randomized, crossover evaluation of the effect of propranolol, nadolol and placebo on syncope recurrence and patients' well-being. [2002.08.07]
Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. [2001.08.30]
Influence of beta-adrenoceptor antagonists on the pharmacokinetics of rizatriptan, a 5-HT1B/1D agonist: differential effects of propranolol, nadolol and metoprolol. [2001.07]
Comparison of the effects of nadolol and bisoprolol on the isoprenaline-evoked dilatation of the dorsal hand vein in man. [2001.06]
Endoscopic variceal ligation plus nadolol and sucralfate compared with ligation alone for the prevention of variceal rebleeding: a prospective, randomized trial. [2000.09]
Long-term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. [2000.02]
Effect of beta-adrenoreceptor blockade with nadolol on the duration of local anesthesia. [1999.12]
Comparison of the effects of nadolol and bisoprolol on noradrenaline-evoked venoconstriction in man in vivo. [1998.03]
Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Gruppo-Triveneto per L'ipertensione portale (GTIP) [1996.12.21]
Adjunctive nadolol in the treatment of acutely aggressive schizophrenic patients. [1996.10]
Bioequivalence of a highly variable drug: an experience with nadolol. [1996.07]
Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. [1996.06.20]
Bioequivalence of two tablet formulations of nadolol using single and multiple dose data: assessment using stereospecific and nonstereospecific assays. [1996.03]
Long-term effect of nadolol or nadolol plus isosorbide-5-mononitrate on renal function and ascites formation in patients with cirrhosis. GTIP Gruppo Triveneto per l'Ipertensione Portale. [1995.09]
The effects of lower than conventional doses of oral nadolol on relative beta 1/beta 2-adrenoceptor blockade. [1994.08]
[Nadolol as an adjuvant to sclerotherapy of esophageal varices for prevention of recurrent hemorrhaging] [1994.07]
Effects of captopril and nadolol on renal hemodynamics in patients with essential hypertension. [1994]
Effects of nadolol on hemodynamic and hemostatic responses to potential mental and physical triggers of myocardial infarction in subjects with mild systemic hypertension. [1993.07.01]
A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy. [1993.06]
Long-term double-blind evaluation of amlodipine and nadolol in patients with stable exertional angina pectoris. The Investigators of Study 152. [1993.01]
Nadolol to treat aggression and psychiatric symptomatology in chronic psychiatric inpatients: a double-blind, placebo-controlled study. [1992.02]
A placebo-controlled trial of nadolol in the treatment of neuroleptic-induced akathisia. [1991.06]
Comparison of the antihypertensive and renal effects of tertatolol and nadolol in hypertensive patients with mild renal impairment. [1991]
Comparison of hypersensitivity to adrenergic stimulation after abrupt withdrawal of propranolol and nadolol: influence of half-life differences. [1990.09]
Lack of effect of atenolol and nadolol on the metabolism of theophylline. [1990.02]
A double-blind, placebo-controlled study of adjunctive nadolol in the management of violent psychiatric patients. [1990]
Effect of nadolol on plasma lipids in hyperthyroidism. [1989.06]
Comparison of the duration of action of atenolol and nadolol for treatment of angina pectoris. [1988.12.01]
Nadolol versus diltiazem and combination for preventing exercise-induced ischemia in severe angina pectoris. [1988.09.01]
Effects of nadolol on arrhythmias during laparoscopy performed under general anaesthesia. [1988.09]
Nadolol for prophylaxis of gastrointestinal bleeding in patients with cirrhosis. A randomized trial. [1988.08]
Acute effects of tertatolol and nadolol on systemic and renal hemodynamics in patients with essential hypertension. [1988.07]
A comparison of carteolol and nadolol in the treatment of stable angina pectoris. [1988.07]
Nadolol can prevent the first gastrointestinal bleeding in cirrhotics: a prospective, randomized study. [1988.01]
The effect of twice daily nadolol on intraocular pressure. [1987.10.15]
A comparison of the effects of oral nadolol and topical timolol on intraocular pressure, blood pressure, and heart rate. [1987.09]
Well-designed clinical trials possibly related to Corgard (Nadolol / Bendroflumethiazide)
A specialized, nurse-run titration clinic: a feasible option for optimizing beta-blockade in non-clinical trial patients. [2010.09]
Early use of TIPS in patients with cirrhosis and variceal bleeding. [2010.06.24]
A randomized, controlled trial of banding ligation plus drug therapy versus drug therapy alone in the prevention of esophageal variceal rebleeding. [2009.06]
Noradrenergic neuromodulation of human attention for emotional and neutral stimuli. [2008.03]
Prevention of recurrent esophageal variceal hemorrhage: review and current recommendations. [2007.11]
Influence of hydrophilic and lipophilic beta-blockers on heart rate, ventricular repolarization and their interrelationship in normal subjects. [2000.05]
In vivo beta3-adrenergic stimulation of human thermogenesis and lipid use. [2000.05]
Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. [2000.02.15]
Memory for emotional material: a comparison of central versus peripheral beta blockade. [1999]
Catecholamines and heart function in heart transplant patients: effects of beta1- versus nonselective beta-blockade. [1998.11]
Memory for emotional events: differential effects of centrally versus peripherally acting beta-blocking agents. [1998.08]
Beta-blocker effects on respiratory sinus arrhythmia and baroreflex gain in normal subjects. [1998.07]
Effects of hydrophilic and lipophilic beta-blockers on heart rate variability and baroreflex sensitivity in normal subjects. [1998.03]
[The effects of chronic beta-blocker administration on respiratory sinus arrhythmia] [1997.02]
Contribution of beta 3-adrenoceptor activation to ephedrine-induced thermogenesis in humans. [1995.09]
Morning increase in ambulatory ischemia in patients with stable coronary artery disease. Importance of physical activity and increased cardiac demand. [1994.02]
Usefulness of amlodipine for angina pectoris. [1994.01.27]
Selectivity of antagonist and partial agonist activity of celiprolol in normal subjects. [1992.10]
Depression during treatment with beta-blockers: results from a double-blind placebo-controlled study. [1992.03]
Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. Franco-Italian Multicenter Study Group. [1991.05.30]
Comparison of hypokalaemic, electrocardiographic and haemodynamic responses to inhaled isoprenaline and salbutamol in young and elderly subjects. [1991]
Beta-blocker duration of action and implications for therapy. [1990.11.06]
Plasma catecholamine responses to exercise after training with beta-adrenergic blockade. [1990.02]
Behavioral and physiological effects of a beta blocker and relaxation therapy on mild hypertensives. [1989.09]
Beta-blockade disappearance rate predicts beta-adrenergic hypersensitivity. [1989.09]
Effects of beta 1- vs. beta 1 + beta 2-blockade on exercise endurance and muscle metabolism in humans. [1989.02]
Cigarette smoking interferes with treatment of hypertension. [1988.10]
Other research related to Corgard (Nadolol / Bendroflumethiazide)
The effects of acute and chronic nadolol treatment on beta2AR signaling in HEK293 cells. [2011.02]
[Comparative study of the effectiveness of topiramate and nadolol in the preventive treatment of episodic migraine in independent series of patients] [2010.05.01]
'Orphan drugs' in cardiology: nadolol and quinidine. [2010.02]
Controlled trial of ligation plus nadolol versus nadolol alone for the prevention
of first variceal bleeding. [2010]
Effects of antalarmin and nadolol on the relationship between social stress and pulmonary metastasis development in male OF1 mice. [2009.12.14]
Effect of nadolol injected prior to CRH on stress-induced plasma corticosterone level in rat. [2009.10]
The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study. [2008]
Impact of preventive therapy with nadolol and topiramate on the quality of life of migraine patients. [2007.08]
Primary prophylaxis with nadolol in cirrhotic patients: Doppler patterns of splanchnic hemodynamics in good and poor responders. [2006.02]
Disagreement between acute and chronic haemodynamic effects of nadolol in cirrhosis: a pathophysiological interpretation. [2005.09.01]
Nadolol inhibits reactive oxygen species generation by leukocytes and linoleic acid oxidation. [2000.08.15]
Severe acne as a side effect of propranolol and nadolol in a migraineur. [1999.11]
[Chronopharmacokinetics of nadolol in patients with arterial hypertension] [1997.09]
Hemodynamic evaluation of the addition of isosorbide-5-mononitrate to nadolol in cirrhotic patients with insufficient response to the beta-blocker alone. [1997.07]
A pilot study of nadolol for overt aggression in developmentally delayed individuals. [1997.06]
Effects of chronic therapy with nadolol on portal hemodynamics and on splanchnic impedance indices using Doppler sonography: comparison between acute and chronic effects. [1997.02]
Effects of nadolol and its combination with atrial pacing on rate-enhanced ventricular premature complexes. [1996.11.15]
The effect of nadolol on heart rate and the standard deviation of the RR intervals. [1995.02]
Duplex Doppler sonographic evaluation of splanchnic and renal effects of single agent and combined therapy with nadolol and isosorbide-5-mononitrate in cirrhotic patients. [1994.12]
Reducing effect of nadolol on serum levels of free thyroid hormones in hyperthyroidism. [1994.12]
Circadian and power spectral changes of RR and QT intervals during treatment of patients with angina pectoris with nadolol providing evidence for differential autonomic modulation of heart rate and ventricular repolarization. [1994.07.15]
Nadolol for lithium tremor in the presence of liver damage. [1994.03]
Pharmacokinetics of nadolol in children with supraventricular tachycardia. [1992.11]
Differential exercise effects of captopril and nadolol in patients with essential hypertension. [1992.08]
Enalapril versus combined enalapril and nadolol treatment: effects on blood pressure, heart rate, humoral variables, and plasma potassium at rest and during exercise in hypertensive patients. [1992.06]
Efficacy and safety of intravenous and oral nadolol for supraventricular tachycardia in children. [1992.03.01]
|
